Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute Inc.

Rezolute ( ($RZLT) ) has issued an update. On November 10, 2025, Rezolute, Inc. held an investor event to update stakeholders on the Ersodetug deve...

Rezolute Highlights Ersodetug Development at Investor Event

Jefferies analyst Maury Raycroft maintained a Buy rating on Rezolute today and set a price target of $15.00. According to TipRanks, Raycroft is a 4...

Rezolute (RZLT) Receives a Buy from Jefferies

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Rezolute, with a price target of $14.00. According to TipR...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RZLT	$9.83	+1.87%	1.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RZLT	$9.83	+1.9%	1.34M
3
4
5
6

RZLT

RZLT

No Data Available

Get Rezolute Inc. Data in Excel

Get Rezolute Inc. Data in Excel